HCPCS Service Codes - Medical care

HCPCS Service Code 1 for Medical care.

HCPCS Type of Service (TOS) code is an indicator that the contractor places on Form CMS-1500. The indicator is mainly used for data purposes, however in some instances, it affects payment. All HCPCS codes have a corresponding TOS indicator.

Below are all available HCPCS TOS codes. Find an HCPCS code based on the type of service.

HCPCS Codes for Medical care

  • M1497

    Documentation of falls not performed due to medical reasons (e.g., syncope, vertigo and related disorders, restless leg syndrome, tourette syndrome/tic disorder, back pain, concussion/mild traumatic brain injury (mtbi), cervical dystonia, or epilepsy)

  • M1498

    Diagnostic radiology mips value pathway

  • M1499

    Interventional radiology mips value pathway

  • M1500

    Neuropsychology mips value pathway

  • M1501

    Pathology mips value pathway

  • M1502

    Podiatry mips value pathway

  • M1503

    Vascular surgery mips value pathway

  • Q0081

    Infusion therapy, using other than chemotherapeutic drugs, per visit

  • Q0083

    Chemotherapy administration by other than infusion technique only (e.g., subcutaneous, intramuscular, push), per visit

  • Q0084

    Chemotherapy administration by infusion technique only, per visit

  • Q0085

    Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit

  • Q0091

    Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory

  • Q0138

    Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)

  • Q0139

    Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)

  • Q0144

    Azithromycin dihydrate, oral, capsules/powder, 1 gram

  • Q0155

    Dronabinol (syndros), 0.1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0161

    Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0162

    Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0163

    Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen

  • Q0164

    Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0166

    Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen

  • Q0167

    Dronabinol, 2.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0169

    Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0173

    Trimethobenzamide hydrochloride, 250 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0174

    Thiethylperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0175

    Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0177

    Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0180

    Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen

  • Q0181

    Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

  • Q0515

    Injection, sermorelin acetate, 1 microgram

  • Q2004

    Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml

  • Q2009

    Injection, fosphenytoin, 50 mg phenytoin equivalent

  • Q2017

    Injection, teniposide, 50 mg

  • Q2040

    Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

  • Q2041

    Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

  • Q2042

    Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

  • Q2043

    Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion

  • Q2050

    Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg

  • Q2053

    Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

  • Q2054

    Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

  • Q2055

    Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

  • Q2056

    Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

  • Q2057

    Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose

  • Q2058

    Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion

  • Q3001

    Radioelements for brachytherapy, any type, each

  • Q3027

    Injection, interferon beta-1a, 1 mcg for intramuscular use

  • Q3028

    Injection, interferon beta-1a, 1 mcg for subcutaneous use

  • Q4074

    Iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms

  • Q4081

    Injection, epoetin alfa, 100 units (for esrd on dialysis)

  • Q4082

    Drug or biological, not otherwise classified, part b drug competitive acquisition program (cap)